Tag Archives: investing

RESI Europe 2026 IPC Finalists 

10 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to announce the finalists for the Innovator’s Pitch Challenge (IPC) at RESI Europe 2026, taking place in Lisbon during the week of March 23. The event will bring together early-stage life science and healthcare innovators with a global community of investors seeking opportunities across drugs, devices, diagnostics, and digital health (4Ds).

This year’s IPC will feature over 20 presenting companies, with finalists pitching their technologies in dedicated sessions throughout the conference. These startups represent a diverse range of innovations aimed at solving critical healthcare challenges and advancing the next generation of life science breakthroughs.

The IPC gives founders the opportunity to pitch directly to active investors, including venture capital firms, family offices, corporate venture groups, and angel investors. Presenting companies receive valuable feedback from investor judges while gaining visibility among the investors and strategic partners attending RESI Europe.

Finalists will also have opportunities to connect with investors through RESI’s partnering system, as well as continue conversations during networking sessions and throughout the conference.

About the RESI Innovator’s Pitch Challenge

The IPC is a cornerstone of the RESI conference series. Each pitch session brings together a coordinated panel of investors who provide interactive feedback and questions designed to help founders refine their fundraising strategy and investment narrative.

Companies selected as IPC finalists receive RESI conference registration, the opportunity to present live to investors, and the chance to build relationships with members of the RESI investment community.

Join Us at RESI Europe 2026

RESI Europe 2026 will bring together founders, investors, and strategic partners for a full day of programming including investor panels, workshops from sponsors, networking opportunities, and the Innovator’s Pitch Challenge.

Attendees will have the opportunity to engage with the early-stage life science ecosystem through structured partnering meetings and educational sessions focused on fundraising and company development.

Register for RESI Europe

Meet the RESI Europe 2026 Innovator’s Pitch Challenge Finalists:

Applications Now Open for RESI San Diego

The Innovator’s Pitch Challenge at RESI San Diego offers life science startups the opportunity to present directly to a curated panel of active investors and receive real-time, constructive feedback. Each pitch includes a live Q&A with investor judges and extended exposure through participation in the IPC exhibition hall.

Apply to Pitch at RESI San Diego

 

Tags: , , , , , , , , , , , ,

Fundraising Bootcamp Ahead of RESI Europe 2026: Preparing Founders for Investor Engagement 

10 Mar

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation (LSN), in collaboration with Cuatrecasas, will host an exclusive Fundraising Bootcamp in Lisbon ahead of RESI Europe 2026, offering early-stage life science and healthcare executives a focused opportunity to refine their fundraising strategy and strengthen investor engagement skills. 

Taking place the day before the conference, the bootcamp will bring together founders, investors, and industry experts for an interactive session designed to help companies better position themselves for capital and partnerships within the global life science ecosystem. 

Event Details 

Date and Time: Sunday, March 22, 2026 | 2:00 PM – 5:30 PM
Location: Cuatrecasas Law Firm
Av. Fontes Pereira de Melo 6
1050-121 Lisboa, Portugal
Cost: Free to attend (registration required) 

This workshop will focus on practical, real-world fundraising insights that early-stage companies can immediately apply when engaging with investors at RESI Europe and beyond. Participants will hear directly from experienced professionals who work with startups and investors across the life science sector. 

Agenda Highlights 

Signal, Legibility, and Risk Mitigation in Global Fundraising 
Learn how investors interpret signals when evaluating early-stage companies and how founders can structure their development plans to become more “legible to capital.” The discussion will also explore strategies for mitigating risk in global fundraising environments. 

Shark Tank Session (Company Pitch) 
Selected companies will have the opportunity to present their pitch and receive direct feedback from experienced investors and industry professionals in an interactive format designed to sharpen messaging and highlight areas for improvement. 

Networking 
The bootcamp will conclude with time for founders and participants to connect with fellow entrepreneurs, investors, and industry experts before the start of RESI Europe. 

This pre-conference session provides a valuable opportunity for innovators preparing for RESI Europe to strengthen their fundraising approach, refine their investor messaging, and begin building connections within the RESI community. 

Space is limited, and applications will be accepted in the order they are received. 

Life Science Nation looks forward to welcoming founders and investors to Lisbon for this interactive fundraising session ahead of RESI Europe 2026. 

Sign up for Bootcamp

Tags: , , , , , , , , , ,

RESI San Diego 2026: Investor Panel Lineup Announced 

10 Mar

By Momo Yamamoto, Senior Investor Research Analyst, LSN

Life Science Nation (LSN) has announced the investor panel lineup for RESI San Diego 2026, taking place June 22 at the JULEP Venue in San Diego during Convention Week, followed by four days of virtual partnering on June 23–24 and June 29–30. The hybrid format combines in-person networking with extended virtual partnering, giving founders and investors additional opportunities to continue conversations and schedule meetings beyond the live event.

Investor panels are a cornerstone of the RESI conference series, bringing together active investors and strategic partners to share perspectives on the evolving life science funding environment. These sessions offer founders and executives the opportunity to hear directly from investors about how they evaluate opportunities across drugs, devices, diagnostics, and digital health.

This year’s discussions will explore several key themes shaping early-stage investment. Topics will include how emerging companies can successfully engage pharmaceutical partners, what strategic investors and corporate venture capital groups are prioritizing in today’s market, and how medtech innovators can position themselves to attract both financial and strategic partners. Panels will also examine investment trends in diagnostics and oncology, the growing role of artificial intelligence in healthcare innovation, and the challenges many startups face when moving from seed capital to institutional venture funding.

RESI San Diego 2026 Investor Panels

Time  Panel Title 
9AM  Inside Pharma Partnering 
How Early-Stage Companies Can Engage Pharma 
10AM  Strategic Partnerships in Medtech 
What the Next Generation of Device Companies Must Deliver 
11AM  Strategic Capital: The Role of CVCs 
Investing Where Innovation Meets Industry
1PM  New Frontiers in Diagnostics 
Investing in Technologies Enabling Earlier Disease Detection 
2PM  Emerging Approaches in Cancer Therapies 
How New Modalities Are Standing Out in a Competitive Market 
3PM  AI at the Frontlines of Healthcare Innovation 
Building Scalable Companies at the Intersection of Data and Medicine 
4PM  Crossing the Venture Gap 
Moving from Seed Funding to Venture Rounds 
Register for RESI San Diego
Apply to Speak at RESI San Diego

In addition to investor panels, RESI San Diego will feature the Innovator’s Pitch Challenge, where selected startups present their technologies directly to investor judges in an interactive pitch format. The conference also offers extensive one-on-one partnering opportunities, allowing attendees to schedule meetings with investors, strategic partners, and industry leaders through the RESI partnering system.

Held during San Diego’s broader biotech Convention Week, RESI San Diego provides a focused environment for early-stage companies to connect with active healthcare investors and strategic partners. The event brings together venture capital firms, family offices, corporate venture groups, and industry leaders seeking opportunities across drugs, devices, diagnostics, and digital health.

Register today to secure your place at RESI San Diego 2026 and connect with investors shaping the future of healthcare innovation. Super Early Bird rates are available through April 17.

Apply to Pitch at RESI San Diego

Tags: , , , , , , , , , , , , , , ,

Hot Investor Mandate: Asia-Based Investment Manager Invests in Healthcare and Life Sciences-Focused Funds and Companies Across the Globe

10 Mar

An investment manager founded in 2021 and headquartered in Asia primarily operates as a fund-of-funds, allocating capital to healthcare and life sciences-focused investment vehicles including venture capital, private equity, and public market funds. In addition to fund commitments, the firm also participates directly in company financings through special purpose vehicles.  

For direct investments, the firm takes a flexible approach but typically participates in later financing rounds after gaining a deeper understanding of the company and its development trajectory. The firm has no specific preference between leading or co-investing and evaluates opportunities globally.  

The firm is broadly interested in companies operating in biotechnology, medical technology, and digital health.  

The firm does not impose specific requirements regarding company structure or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Investment Arm of Large Healthcare Enterprise Invests and Partners With Innovations With China and Global Market Potential

10 Mar

The firm is the investment arm of a diversified healthcare enterprise headquartered in Asia with international operations. The broader organization operates across medical innovation incubation, manufacturing, and large-scale commercialization, with a strong focus on technology-driven healthcare solutions and intellectual property development. Through its investment activities, the firm supports innovative healthcare companies by providing capital as well as access to industrial capabilities and commercialization infrastructure. The broader organization maintains a large healthcare distribution platform serving hospitals and pharmacies nationwide, enabling portfolio companies to access substantial market channels. The firm evaluates global investment opportunities with strong potential for commercialization in the China market.  

The firm focuses on life sciences and healthcare opportunities spanning therapeutics, diagnostics, medical devices, R&D tools, and AI-enabled healthcare platforms. Areas of particular interest include oncology and immuno-oncology, advanced therapeutic modalities such as cell and gene therapy, and innovative medical technologies with clear clinical application. Through its technology innovation initiatives, the organization collaborates with research institutions to identify and develop original scientific breakthroughs, including first-in-class medicines and novel medical devices. While the firm frequently evaluates later-stage assets and partnership opportunities, it also considers early-stage technologies with strong scientific differentiation and long-term commercial potential.  

From a company and partnership perspective, the firm prioritizes opportunities with meaningful relevance to the China healthcare market and the ability to leverage the organization’s regulatory, manufacturing, and commercial infrastructure. The firm looks for strong scientific foundations, clear unmet clinical needs, differentiated product positioning, and credible strategies for market entry and expansion. Portfolio companies may benefit from support across R&D collaboration, industrial incubation, regulatory strategy, manufacturing scale-up, and nationwide commercialization. The firm maintains a flexible investment approach and may participate as either a lead investor or a co-investor depending on the opportunity and partnership structure. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

Hot Investor Mandate: Family-Office Backed Investment Vehicle Seeks Innovative Medtech Opportunities in US, Western Europe, and Asia

10 Mar

The firm is a joint venture investment vehicle established by a family office and a strategic investment partner. The firm focuses on later-stage medical device opportunities, particularly Series A and Series B companies approaching regulatory approval. The firm primarily evaluates opportunities in the United States and Western Europe, while remaining open to select companies based in Asia. Typical check sizes range from approximately $500K to $1.5M, and the firm prefers to lead transactions. The firm may also co-invest alongside affiliated investment vehicles to support later-stage, revenue-generating companies that demonstrate a clear path to exit within a relatively short time horizon. Through long-standing industry relationships, the firm helps introduce portfolio companies into a specialized medical technology ecosystem to accelerate growth and commercialization.  

The firm evaluates opportunities across medical device categories but maintains a strong focus on implantable technologies. Core areas of interest include neuromuscular and musculoskeletal indications, particularly orthopedic and spine implants. The firm also reviews opportunities in cardiology, vascular and peripheral devices, surgical technologies, and select oncology-related technologies. Companies should typically be approaching regulatory approval and demonstrate validated technology and clinical utility.  

From a company and management team perspective, the firm requires board representation and at minimum takes an observer seat in portfolio companies. The firm seeks companies with proven technology, clear regulatory pathways, and strong commercial potential within established clinical markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

RESI Europe 2026 Investor Panels Take the Stage in Lisbon 

3 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is preparing for RESI Europe 2026, taking place March 23 in person at the EPIC SANA Lisboa Hotel, followed by four days of virtual partnering. 

The RESI Europe panel program will bring together active healthcare investors to discuss the sectors and strategies shaping early-stage capital formation across therapeutics, devices, diagnostics, digital health, and enabling technologies. As European companies increasingly look beyond domestic markets for capital, the conversations will reflect cross-border investment dynamics and milestone expectations in today’s disciplined funding environment. 

These panels are structured as constructive dialogue between investors and fundraising CEOs. Attendees will hear directly from venture, corporate, and strategic investors about how opportunities are evaluated, what readiness looks like at Seed and Series A, and how companies can engage the right partnering environments at the right time. 

Join the panelists at RESI Europe 2026 and engage directly with the investors shaping early-stage healthcare capital. 

Special Offer: Register for a RESI Europe 5-day hybrid ticket and receive a complimentary second attendee pass. This promotion applies to standard hybrid registrations and provides an opportunity to bring a colleague to maximize partnering coverage across all five days. 

Register for RESI Europe and secure meetings with active healthcare investors in Lisbon this March. 

Register for RESI Europe
RESI Europe Investor Panel Speakers
Raj-Airey
Raj Airey
Convergence Partners AG		 Rosie-Barnett
Rosie Barnett
Delin Ventures		 Amine-Benmoussa
Amine Benmoussa
Karista
Marcos-Casado
Marcos Casado
Invivo Partners		 Bettina-Ernst
Bettina Ernst
BERNINA BioInvest		 Navin-Govind-
Navin Govind
Evidence Ventures

William Hsu
Life Science Angels		 Mohammad-Khobreh
Mohammad Khobreh
NG Bio		 Carsten-Laue
Carsten Laue
M2Care
Chloe-Lepretre
Chloé Lepretre
Servier		 Mukul-Mohanty
Mukul Mohanty
Truffle Capital		 Luka-Nicin
Luka Nicin
Pace Ventures
Joseph-Oliver
Joseph Oliver
Stanford Angels of the UK		 Soyoung-Park
Soyoung Park
1004 Venture Partners		 Francisco-Pinto
Francisco Pinto
Bynd Venture Capital
Bibi-Sattar-Marques
Bibi Sattar Marques
Buenavista Equity Partners		 Jeff-Stinson
Jeff Stinson
HTA		 Mercedes-Tuin
Mercedes Tuin
Heran Partners
Carmel-van-den-Berk
Carmel van den Berk
Brightlands Venture Partners		 Mariette-van-der-Velden
Mariette van der Velden
Curie Capital		 Giulia-Vestri
Giulia Vestri
Claris Ventures
Yu-Zhang
Yu Zhang
FaaS Capital

Tags: , , , , , , , , , , , ,

← Older Entries
Newer Entries →